Related Experiment Video
Updated: May 16, 2025
Methodology for Sputum Induction and Laboratory Processing
Published on: December 17, 2017
The Effect of Mepolizumab on Blood Eosinophil Subtype Distribution and Granule Protein Gene Expression in Severe
Airidas Rimkunas1, Andrius Januskevicius1, Egle Vasyle1
1Laboratory of Pulmonology, Department of Pulmonology, Lithuanian University of Health Sciences, Kaunas, Lithuania.
Purpose:
Mepolizumab, which causes a decrease in the number of blood eosinophils, is used to treat patients with severe eosinophilic asthma (SEA). However, there is a relative lack of data on dynamic changes in blood eosinophil subtype distribution and their granule protein expression following anti-interleukin (IL)-5 treatment. Our objective was to evaluate blood inflammatory-like (iEOS-like) and resident-like (rEOS-like) eosinophil subtype distribution and CLC, EDN, EPX, ECP, and MBP gene expression following up to 24 weeks of treatment with mepolizumab in SEA patients.
Patients And Methods:
Ten free of oral steroids SEA patients and 9 healthy control subjects (HS) were included. Patients were treated with mepolizumab 100 mg subcutaneously/4 weeks, and investigation tests were performed at 0, 4, 12, and 24 weeks. Blood eosinophils were isolated by Ficoll centrifugation and magnetic separation, then subtyped using magnetic separation against CD62L. Gene expression investigation was done using quantitative real time-polymerase chain reaction analysis.
Results:
Approximately three-quarters of isolated blood eosinophils were iEOS-like cells before mepolizumab treatment, p<0.01. Blood eosinophil granule protein gene expression was increased in SEA patients compared to the HS, p<0.05, and iEOS-like cells EPX, MBP, and CLC gene expressions were higher than rEOS-like cells, p<0.05. Following 4, 12, and 24 weeks of treatment with mepolizumab, residual blood eosinophils shifted towards rEOS-like cells, p<0.05, and CLC, EPX, ECP, and MBP gene expression of both eosinophil subtypes decreased to HS levels.
Conclusion:
Treating SEA patients with mepolizumab shifts blood eosinophil subtype distribution towards rEOS-like cells and reduces granule protein gene expression levels to those of healthy individuals.
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:26Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:24Antiasthma Drugs: Methylxanthines
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
01:17Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...